Cited by 714Cancer Mechanisms and TherapyProtein Kinase Regulation and GTPase SignalingComputational Drug Discovery Methods

The DOI matches its Crossref record; 100 of the 104 references it cites were found in a registry or an index.

Targeting the cancer kinome through polypharmacology

Open access

Knight, Zachary A., Lin, Henry, Shokat, Kevan M.·2010·Nature reviews. Cancer

DOI 10.1038/nrc2787PMC PMC2880454

Open this paper in CoChat — free account

Abstract

Kinase inhibitors are the largest class of new cancer drugs. However, it is already apparent that most tumours can escape from the inhibition of any single kinase. If it is necessary to inhibit multiple kinases, how do we choose which ones? In this Opinion article, we discuss some of the strategies that are currently being used to identify new therapeutic combinations of kinase targets.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nrc2787

Cites

100 of 100 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S. M., Négrier, S., Szczylik, C. A., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,752
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J., Lydon, N., Kantarjian, H. M., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,237
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B. J., Eisen, T. G., Stadler, W. M., Szczylik, C. A., Oudard, S. M., Siebels, M., Négrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Specificity and mechanism of action of some commonly used protein kinase inhibitors
DAVIES, S. P., Reddy, H., Caivano, M., & Cohen, P. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3510095 · Cited by 4,366

Show all 104 references

Research works printed but not linked: 1

Winslow, R. AstraZeneca, Merck to Test Cancer Drugs in 'Cocktail'. The Wall Street Journal [online] , (2009).

Sorted by citations

Items 501–600 of 714

Highly Multiplexed Kinase Profiling in Spleen with Targeted Mass Spectrometry Reveals Kinome Plasticity across Species
Marholz, L. J., Federspiel, J. D., Suh, H., & Ocaña, M. F. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00199 · Cited by 5
Small molecule induces mitochondrial impairment in colon cancer cells
Shinde, S., Chhabria, D., Ingle, J., Kumar, M., Kirubakaran, S., & Basu, S. (2022) · New Journal of Chemistry · doi:10.1039/d2nj03242b · Cited by 6
Pharmacological approaches to understanding protein kinase signaling networks
Stephenson, E. H., & Higgins, J. M. G. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1310135 · Cited by 6
An Insight Into the Structure–Activity Relationship Studies of Anticancer Medicinal Attributes of 7-Azaindole Derivatives: A Review
Sharma, N., Chaudhary, A., & Sachdeva, M. (2023) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0216 · Cited by 6
Fluorometric detection of protein kinase Cα activity based on phosphorylation-induced dissociation of a polyion complex
Toita, R., Mori, T., Naritomi, Y., Kang, J., Shiosaki, S., Niidome, T., & Katayama, Y. (2012) · Analytical Biochemistry · doi:10.1016/j.ab.2012.01.036 · Cited by 6
Report on the use of non‐clinical studies in the regulatory evaluation of oncology drugs
Hayakawa, Y., Kawada, M., Nishikawa, H., Ochiya, T., Saya, H., Seimiya, H., Yao, R., Hayashi, M., Kai, C., Matsuda, A., et al. (2016) · Cancer Science · doi:10.1111/cas.12857 · Cited by 6
Targeting Protein Synthesis, Folding, and Degradation Pathways in Cancer
Pasqua, E., Wilding, B., Cheeseman, M. D., & Jones, K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12395-9 · Cited by 6
Computational Methods in Multitarget Drug Discovery
Bottegoni, G., & Cavalli, A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-08-101011-2.00009-x · Cited by 6
Sphingosine simultaneously inhibits nuclear import and activates PP2A by binding importins and PPP2R1A
Jayashankar, V., Kubiniok, P., McCracken, A. N., Gentry, R. G., Eckenstein, K. H., Sernissi, L., Vece, V., Garsi, J.-B., Valles, S. Y., Jung, S., et al. (2025) · The EMBO Journal · doi:10.1038/s44318-025-00490-5 · Cited by 5
“Polypharmacology is a validated strategy to overcome drug resistance (Vincent et al, 2022; Knight et al, 2010).”
Design, synthesis and biological evaluation of new Myo-inositol derivatives as potential RAS inhibitors
Hussain, J., Chhabria, D., & Kirubakaran, S. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127290 · Cited by 5
Extracellular sulfatases as potential blood-based biomarkers for early detection of lung cancer
Yang, Y., Jablons, D. M., & Lemjabbar‐Alaoui, H. (2021) · Experimental Lung Research · doi:10.1080/01902148.2021.1885525 · Cited by 5
“These findings highlight the complexity of lung cancer and the need for novel diagnostic and therapeutic tools that reflect and impact changes in more than one signaling pathway.(8) Heparan sulfate proteoglycans (HSPGs) consist of core proteins modified by the covalent addition of Heparan sulfate (HS) chains containin…”
Background
High Efficacy and Drug Synergy of HDAC6-Selective Inhibitor NN-429 in Natural Killer (NK)/T-Cell Lymphoma
Garcha, H. K., Nawar, N., Sorger, H., Erdogan, F., Aung, M. M. K., Sedighi, A., Manaswiyoungkul, P., Seo, H., Schönefeldt, S., Pölöske, D., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15111321 · Cited by 5
Discovery of Kinase and Carbonic Anhydrase Dual Inhibitors by Machine Learning Classification and Experiments
Kim, M., Pandit, S., & Jee, J. (2022) · Pharmaceuticals · doi:10.3390/ph15020236 · Cited by 6
Palbociclib (PD 0332991) Interaction with Kinases. Theoretical and Comparative Molecular Docking Study
Aceves-Hernández, J. M., Nicolás‐Vázquez, M. I., Rivera, J. L. G., Godínez, A. E., Flores, J. M., Guzmán, J. D. J. C., & Castaño, V. M. (2023) · Chemistry & Biodiversity · doi:10.1002/cbdv.202200554 · Cited by 5
“[7–9] Nevertheless, despite the huge investments and the large arsenal of drugs, fighting cancer with kinase inhibitors is still severely hampered since most tumors can escape inhibition by a single kinase.([10]) Protein kinases are enzymes that phosphorylate other proteins (typical) and other times different molecule…”
Background
Innovative strategies for measuring kinase activity to accelerate the next wave of novel kinase inhibitors
Veth, T. S., Kannegieter, N. M., de Graaf, E. L., Ruijtenbeek, R., Joore, J., Ressa, A., & Altelaar, M. A. F. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.103907 · Cited by 5
Bench to bedside: mechanistic principles of targeting the RAF kinase in melanoma
Rajakulendran, T., & Adam, D. N. (2014) · International Journal of Dermatology · doi:10.1111/ijd.12724 · Cited by 5
Self‐Assembled Oleic Acid Nanoparticle Mediated Inhibition of Mitogen‐Activated Protein Kinase Signaling in Combination with DNA Damage in Cancer Cells
Palvai, S., More, P. A., Mapara, N., Nagraj, J., Chowdhury, R., & Basu, S. (2015) · ChemNanoMat · doi:10.1002/cnma.201500195 · Cited by 5
Temperature does matter—an additional dimension in kinase inhibitor development
Strauch, M., & Heyd, F. (2020) · FEBS Journal · doi:10.1111/febs.15564 · Cited by 5
Covalent Inhibition of the Human 20S Proteasome with Homobelactosin C Inquired by QM/MM Studies
Serrano-Aparicio, N., Ferrer, S., & Świderek, K. (2022) · Pharmaceuticals · doi:10.3390/ph15050531 · Cited by 5
“This is especially important in new strategies used to de‐ sign polypharmacological anticancer drugs [67] where hBelC could serve as a template for the dual inhibition of the proteasome and fatty acid as proposed by Romo and co‐ workers.”
Background
Proteomics approaches in the identification of cancer biomarkers and drug discovery
Nisar, N., Mir, S. A., Kareem, O., & Pottoo, F. H. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95072-5.00001-8 · Cited by 5
Activation of Pro-survival CaMK4β/CREB and Pro-death MST1 signaling at early and late times during a mouse model of prion disease
Shott, R. H., Majer, A., Frost, K. L., Booth, S. A., & Schang, L. M. (2014) · Virology Journal · doi:10.1186/1743-422x-11-160 · Cited by 5
“For example, protein kinase inhibitors are the largest group of new cancer therapeutics [26].”
Background
Structure-Based Kinase Profiling To Understand the Polypharmacological Behavior of Therapeutic Molecules
Dutta, D., Das, R., Mandal, C., & Mandal, C. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00227 · Cited by 5
Explicit representation of protein activity states significantly improves causal discovery of protein phosphorylation networks
Liu, J., Ma, X., Cooper, G. F., & Lu, X. (2020) · BMC Bioinformatics · doi:10.1186/s12859-020-03676-2 · Cited by 5
Effect of peptide content on the regulation of transgene expression by protein kinase Cα-responsive linear polyethylenimine-peptide conjugates
Toita, R., Kang, J., Kim, C. W., Shiosaki, S., Mori, T., Niidome, T., & Katayama, Y. (2014) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2014.09.004 · Cited by 5
A simple set-and-mix assay for screening of protein kinase inhibitors in cell lysates
Asami, Y., Oishi, J., Kitazaki, H., Kamimoto, J., Kang, J., Niidome, T., Mori, T., & Katayama, Y. (2011) · Analytical Biochemistry · doi:10.1016/j.ab.2011.06.041 · Cited by 5
Fluorescent Polyion Complex Nanoparticle That Incorporates an Internal Standard for Quantitative Analysis of Protein Kinase Activity
Nobori, T., Shiosaki, S., Mori, T., Toita, R., Kim, C. W., Nakamura, Y., Kishimura, A., Niidome, T., & Katayama, Y. (2014) · Bioconjugate Chemistry · doi:10.1021/bc500142j · Cited by 5
Role of metal cations and oxyanions in the regulation of protein arginine phosphatase activity of YwlE from Bacillus subtilis
Huang, B., Zhao, Z., Huang, C., Zhao, M., Zhang, Y., Liu, Y., Liao, X., Huang, S., & Zhao, Y. (2020) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2020.129698 · Cited by 5
Structural and Functional View of PolypharmacologyPreprint
Moya‐García, A. A., Adeyelu, T. T., Krüger, F. A., Dawson, N. L., Lees, J. G., Overington, J. P., Orengo, C. A., & Ranea, J. A. G. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/044289 · Cited by 5
Multiple Steps to Activate FAK’s Kinase Domain: Adaptation to Confined Environments?
Herzog, F. A., & Viola Vogel, B. (2013) · Biophysical Journal · doi:10.1016/j.bpj.2013.04.021 · Cited by 4
“Phosphorylation of proteins is recognized as one of the most important posttranslational modifications, because it is involved in almost every signaling pathway (1–3), and has been the target of various drug developments (4,5).”
Background
Comprehensive Data-Driven Assessment of Non-Kinase Targets of Inhibitors of the Human Kinome
Mobasher, M., Vogt, M., Xerxa, E., & Bajorath, J. (2024) · Biomolecules · doi:10.3390/biom14030258 · Cited by 4
“PKIs were considered as candidate compounds in different therapeutic areas such as cancer [10,11], immunology and inflammation [12], diseases of the central nervous system [13], or metabolic diseases [14].”
Background
Novel Kinase Inhibitors by Reshuffling Ligand Functionalities Across the Human Kinome
Vidović, D., Muskal, S. M., & Schürer, S. C. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci3003842 · Cited by 4
Phenotypic and In Vivo Screening: Lead Discovery and Drug Repurposing
Lipinski, C. A. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734912-00086 · Cited by 4
Sample Preparation and Profiling: Probing the Kinome for Biomarkers and Therapeutic Targets: Peptide Arrays for Global Phosphorylation-Mediated Signal Transduction
Kindrachuk, J., & Napper, S. (2013) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734363-00162 · Cited by 4
Large-scale bioactivity analysis of the small-molecule assayed proteome
Backman, T. W. H., Evans, D. S., & Girke, T. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171413 · Cited by 4
Evaluation of Kinase Inhibitor Selectivity Using Cell‐based Profiling Data
Miljković, F. N., & Bajorath, J. (2018) · Molecular Informatics · doi:10.1002/minf.201800024 · Cited by 4
Systematic assessment of structure-promiscuity relationships between different types of kinase inhibitors
Hu, H., & Bajorath, J. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116226 · Cited by 4
SAR Probing of KX2-391 Provided Analogues With Juxtaposed Activity Profile Against Major Oncogenic Kinases
Omar, A. M., Khayat, M. T. A., Ahmed, F., Muhammad, Y. A., Malebari, A. M., Ibrahim, S. M., Khan, M. I., Shah, D. K., Childers, W. E., & El‐Araby, M. E. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.879457 · Cited by 4
Promiscuity analysis of a kinase panel screen with designated p38 alpha inhibitors
González-Medina, M., Miljković, F. N., Haase, G. S., Drueckes, P., Trappe, J., Laufer, S., & Bajorath, J. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.112004 · Cited by 5
Anti-Survival Effect of SI306 and Its Derivatives on Human Glioblastoma Cells
Monteleone, L., Marengo, B., Musumeci, F., Grossi, G., Carbone, A., Valenti, G. E., Domenicotti, C., & Schenone, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071399 · Cited by 4
“Most of the Src inhibitors available today are non-specific and offer cross-reactivity [37].”
Background
Functional phosphosite screening for targeted protein–protein interactions by combining phosphoproteomics strategies and mammalian two-hybrid assays
Guo, M., Xia, Z., & Ma, H. (2011) · Molecular BioSystems · doi:10.1039/c1mb05053b · Cited by 4
A Knowledge-based Integrative Modeling Approach for In-Silico Identification of Mechanistic Targets in Neurodegeneration with Focus on Alzheimer's Disease
Younesi, E. (2014) · Cited by 4
Les inhibiteurs de tyrosine kinase
Robert, J. (2011) · Bulletin du Cancer · doi:10.1684/bdc.2011.1472 · Cited by 4
ICBS and ECBS Chemical Biology Meeting 2015 - Let Them Come to Berlin!
Komatsu, T., & Virdee, S. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00268 · Cited by 4
An Assessment of Kinase Selectivity, Enzyme Inhibition Kinetics and in Vitro Activity for Several Bruton Tyrosine Kinase (BTK) Inhibitors
Corrionero, A., Zhang, X., Alfonso, P., Morris, P. J., Klumpp-Thomas, C. A., Melani, C. J., McKnight, C. G., Phelan, J. D., Holland, D. O., Wilson, K. M., et al. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00412 · Cited by 5
Fluorescence Labels in Kinases: A High-Throughput Kinase Binding Assay for the Identification of DFG-Out Binding Ligands
Simard, J. R., & Rauh, D. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-349-3_8 · Cited by 3
Combination of PI3K/Akt/mTOR inhibitors and PDT in endothelial and tumor cells
Fateye, B. A., & Chen, B. (2011) · Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE · doi:10.1117/12.876042 · Cited by 3
“The clinical potential shown by signal inhibitors is evidenced by the recent increase in number of kinase inhibitors that have proceeded into clinical trials([4-7]).”
Background
Reverse Phase Protein Arrays for Compound Profiling
Moerke, N. J., & Fallahi‐Sichani, M. (2016) · Current Protocols in Chemical Biology · doi:10.1002/cpch.9 · Cited by 3
“…Published online September 2016 in Wiley Online Library (wileyonlinelibrary.com). doi: 10.1002/cpch.9 Copyright C© 2016 John Wiley & Sons, Inc. Reverse Phase Protein Arrays 179 Volume 8 exhibit significant polypharmacology and affect proteins other than their principal target (Knight et al., 2010).”
BackgroundInfluential
A Toolbox of Structural Biology and Enzyme Kinetics Reveals the Case for ERK Docking Site Inhibition
Sammons, R. M., & Dalby, K. N. (2020) · Springer eBooks · doi:10.1007/978-3-030-48283-1_6 · Cited by 3
Challenges in Pharmacotherapy of Neoplastic Diseases – The Search for Addictions
Féron, O. (2010) · Frontiers in Pharmacology · doi:10.3389/fphar.2010.00120 · Cited by 3
“Worse yet, old demons of conventional chemotherapy, namely toxicity and resistance, are now dampening the original enthusiasm (Force et al., 2007; Knight et al., 2010).”
Background
Discovery of a New Bioactive Molecule for Neuroblastoma
Leitão, A., Schramm, A. R., & Eggert, A. (2013) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12148 · Cited by 3
When tight is too tight: Dasatinib and its lower affinity analogue for profiling kinase inhibitors in a three-hybrid split-luciferase system
Ogunleye, L. O., Jester, B. W., Riemen, A. J., Badran, A. H., Wang, P., & Ghosh, I. (2014) · MedChemComm · doi:10.1039/c3md00275f · Cited by 3
Development of kinomic analyses to identify dysregulated signaling pathways in cells expressing cytoplasmic PrP
Shott, R. H., Appanah, C., Grenier, C., Tremblay, G., Roucou, X., & Schang, L. M. (2014) · Virology Journal · doi:10.1186/1743-422x-11-175 · Cited by 3
“such inhibitors are in clinical use, over 500 are involved in approximately 2,700 clinical trials, and thousands more are in various stages of pre-clinical development ([4-6] and summary of [7]).”
Background
Mechanistic and Pharmacological Insights into Modulation of ABC Drug Transporters by Tyrosine Kinase Inhibitors
Shukla, S., Patel, A. S., & Ambudkar, S. V. (2015) · Springer eBooks · doi:10.1007/978-3-319-23476-2_10 · Cited by 3
Oncogenic Signalling Networks and Polypharmacology as Paradigms to Cope with Cancer Heterogeneity
Moya‐García, A. A., Morilla, I., & Ranea, J. A. G. (2014) · Current Proteomics · doi:10.2174/157016461103140922164228 · Cited by 2
Structural Chemogenomics Databases to Navigate Protein–Ligand Interaction Space
Kanev, G. K., Kooistra, A. J., de Esch, I. J. P., & de Graaf, C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12298-x · Cited by 3
Computational Approaches in Multitarget Drug Discovery
Scotti, L., Ishiki, H. M., Duarte, M. C., Oliveira, T. B., & Scotti, L. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7899-1_16 · Cited by 3
Emerging need of advanced drug delivery systems in cancer
Prasher, P., Sharma, M., & Dua, K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85503-7.00032-8 · Cited by 3
Polypharmacology and Adverse Bioactivity Profiles Predict Potential Toxicity and Drug‐Related Adrs
Kaserer, T., Temml, V., & Schuster, D. (2014) · doi:10.1002/9781118783344.ch2 · Cited by 3
The Three Cornerstones of Chemical Biology: Innovative Probes, New Discoveries, and Enabling Tools
Thompson, A. D., Makley, L. N., McMenimen, K. A., & Gestwicki, J. E. (2012) · ACS Chemical Biology · doi:10.1021/cb3001827 · Cited by 3
Ultraviolet Activation of PKD: Implications for Skin Cancer
Bollag, W. B., & Bollag, R. J. (2011) · Future Oncology · doi:10.2217/fon.11.16 · Cited by 3
Polypharmacology in Drug Discovery
Méndez‐Lucio, O., Naveja, J. J., Vite‐Caritino, H., Prieto-Martínez, F. D., & Medina‐Franco, J. L. (2017) · Methods and principles in medicinal chemistry · doi:10.1002/9783527674381.ch1 · Cited by 4
MADSP: predicting anti-cancer drug synergy through multi-source integration and attention-based representation learning
Hong, Y., Zhao, Q., & Wang, J. (2025) · Bioinformatics · doi:10.1093/bioinformatics/btaf326 · Cited by 2
“By acting on multiple targets simultaneously, drugs can overcome cancer cell resistance and improve therapeutic efficacy (Knight et al. 2010).”
Exploratory Covalent Docking of Michael-Acceptor Natural Products at Reactive Cysteines in Cancer Tyrosine Kinases
Lobo, F., de la Lastra, J. M. P., Andrés, C. M. C., Bustamante‐Munguira, E., Andrés, C., & Pérez‐Lebeña, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311390 · Cited by 3
“Occasional hinge/backbone contacts observed with osimertinib suggest potential cross-pocket compatibility, in line with documented cross-reactivity of some TKIs across RTKs [34] (Table 3).”
Computational Multi-target Drug Design
Guruprasad, L., Saxena, S., Banerjee, A., & Boggarapu, G. (2025) · Springer handbooks · doi:10.1007/978-3-031-81728-1_28 · Cited by 2
An integrative system biology approach to unravel potential drug candidates for multiple age related disorders
Srivastava, I., Khurana, P., Yadav, M., & Hasija, Y. (2017) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2017.07.016 · Cited by 2
Network-Pharmacology and Central Nervous System Drug Development
Talevi, A. (2024) · AAPS introductions in the pharmaceutical sciences · doi:10.1007/978-3-031-62604-3_9 · Cited by 2
Small molecules for impairing endoplasmic reticulum in cancer
Mishra, T., Dubey, N., & Basu, S. (2024) · Organic & Biomolecular Chemistry · doi:10.1039/d4ob01238k · Cited by 2
Synthesis of N-subsituted-2-(trifluoromethyl)benzimidazoles as promising EGFR/VEGFR2 dual inhibition through molecular docking studies
Rayes, S. M. E., Ali, I. A. I., Fathalla, W., Ghanem, M. A., El-Sagheer, A. H., & Nafie, M. S. (2024) · Journal of the Iranian Chemical Society · doi:10.1007/s13738-024-03094-8 · Cited by 2
A Gene Family-led Meta-Analysis of Drug-Target Interactions
Cheng, Q., Mehta, S., & Schürer, S. C. (2018) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm.2018.8621087 · Cited by 2
“[43] Knight, Z.”
Compound Structure‐Independent Activity Prediction in High‐Dimensional Target Space
Balfer, J., Hu, Y., & Bajorath, J. (2014) · Molecular Informatics · doi:10.1002/minf.201400051 · Cited by 2
Cancer Tolerance, Resistance, Pathogenicity and Virulence: Deconstructing the Disease State
van Niekerk, G., Loos, B., Nell, T. A., & Engelbrecht, A. (2016) · Future Oncology · doi:10.2217/fon-2015-0024 · Cited by 2
Clinical Need and Rationale for Multi-Target Drugs in Psychiatry
Shahid, M. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734912-00014 · Cited by 2
Data Structures for Compound Promiscuity Analysis: Promiscuity cliffs, Pathways and Promiscuity Hubs Formed by Inhibitors of the Human Kinome
Miljković, F. N., & Bajorath, J. (2019) · Future Science OA · doi:10.2144/fsoa-2019-0040 · Cited by 2
An atlas of the catalytically active liver and spleen kinases in chicken identified by chemoproteomics
Nanduri, B., Gresham, C. R., Hui, W. W. Y., Ou, M. S., Bailey, R. H., & Edelmann, M. J. (2020) · Journal of Proteomics · doi:10.1016/j.jprot.2020.103850 · Cited by 2
Origins and progression of the polypharmacology concept in drug discovery
Bajorath, J. (2024) · Artificial Intelligence in the Life Sciences · doi:10.1016/j.ailsci.2024.100094 · Cited by 2
Systematic identification and characterization of compounds with reliable activity against multiple target proteins from different classes
Srinivasan, S., & Bajorath, J. (2024) · Results in Chemistry · doi:10.1016/j.rechem.2024.101376 · Cited by 2
Case Studies: Selective Inhibitors of Protein Kinases – Exploiting Demure Features
Laird, E. R. (2015) · Methods and principles in medicinal chemistry · doi:10.1002/9783527673643.ch18 · Cited by 2
Anthelmintic drug discovery: Into the future
Geary, T. G., Sakanari, J. A., & Caffrey, C. R. (2016) · doi:10.1002/9781118884799.ch15 · Cited by 2
Computational Approaches for Target Inference
Heßler, G., Grebner, C., & Matter, H. (2019) · Methods and principles in medicinal chemistry · doi:10.1002/9783527818242.ch10 · Cited by 2
Minimal Screening Requirements for Identifying Highly Promiscuous Kinase Inhibitors
Bajorath, J. (2021) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0077 · Cited by 2
A Rapid and Quantitative Detection of Cellular Protein Kinase Activity Based on MALDI-TOF-MS
Otsubo, Y., Ikeda, H., Kamimoto, J., Niidome, T., Mori, T., & Katayama, Y. (2014) · Chemistry Letters · doi:10.1246/cl.131227 · Cited by 1
High-Risk Neuroblastoma Stage 4 (NBS4): Developing a Medicinal Chemistry Multi-Target Drug Approach
Gerges, A., & Canning, U. (2025) · Molecules · doi:10.3390/molecules30102211 · Cited by 1
“Since it is uncommon for multiple targets to mutate simultaneously in different pathways or at various locations within a single cascade pathway, multi-target drugs may also avoid drug resistance brought on by single-target mutations or changes in expression [10].”
Polypharmacology‐Driven Discovery of ZAK‐I‐57: A Potent Multi‐Targeted Benzoxazinone Small Molecule for Hepatocellular Carcinoma Therapy
Khan, S. A., Yang, H., Fan, Y., Chu, C. N., & Lee, T. K. (2025) · MedComm · doi:10.1002/mco2.70291 · Cited by 1
“For instance, polypharmacological compounds have shown efficacy in treating KRAS mutant non-small cell lung cancers, which have proven refractory to conventional single-target agents [12].”
Computational Investigation of Rosolic Acid as an Inhibitor Targeting HER2 in Prostate Cancer Using Virtual Screening, Molecular Docking, and Molecular Dynamics Simulations
Mukherjee, A. G., & Gopalakrishnan, A. V. (2026) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-026-10755-z · Cited by 1
“Such interaction networks are characteristic of clinically optimized kinase inhibitors, which are designed to maximize hydrophobic burial and pocket occupancy in order to enhance binding affinity [ 47].”
Advances in the design and discovery of small-molecule tyrosine kinase inhibitors for breast cancer
Elwaie, T. A., Aref, M. M. A., & Ali, H. I. (2026) · RSC Advances · doi:10.1039/d6ra03011d · Cited by 1
“78,79,122 Their main advantage is simultaneous blockade of pathway redundancy, but broader kinase inhibition may increase o ﬀ -target toxicity and complicate SAR optimization.”
Attacking cancer with molecularly targeted agents
Santoro, M. M., & Carlomagno, F. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.06.011 · Cited by 1
Studying chemical-regulation of intracellular kinase activity by peptide microarray-based assay with gold nanoparticle probes
Li, T., Su, M., Ma, L., Liu, D., & Wang, Z. (2014) · Analytical Methods · doi:10.1039/c4ay02157f · Cited by 1
RET: A Multi-Faceted Gene in Human Cancer
Santoro, M., Carlomagno, F., & Melillo, R. M. (2012) · Endocrinology and Metabolism · doi:10.3803/enm.2012.27.3.173 · Cited by 1
“Multi-targeting or combination therapies may also attenuate resistance formation [67].”
Background
Drug Discovery and Repurposing for Retinoblastoma
Bhinder, B., Mahida, J. P., Ibáñez, G., Champ, K. G., Antczak, C., & Djaballah, H. (2015) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-3-319-19467-7_7 · Cited by 1
Dual Inhibition of Phosphodiesterase-4 and p38 MAP Kinase: A Strategy for Treatment of Chronic Inflammatory Diseases
Albrecht, W., & Laufer, S. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849735346-00137 · Cited by 1
Chemoinformatic Approaches to Target Identification
Gregori‐Puigjané, E., & Keiser, M. J. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734912-00050 · Cited by 1
The Peptide Microarray-Based Resonance Light Scattering Assay for Sensitively Detecting Intracellular Kinase Activity
Li, T., Liu, X., Liu, D., & Wang, Z. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-3037-1_7 · Cited by 1
Applications of promiscuity of FDA-approved kinase inhibitors in drug repositioning and toxicity
Korikani, M., Fathima, N., Nadiminti, G., Akula, S., & Kancha, R. K. (2023) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2023.116469 · Cited by 1
LaF 3 nanoparticle-assisted sensitive detection of protein kinase activity
Fan, Y., Wang, Y., Wang, P., & Li, Z. (2014) · Analytical Methods · doi:10.1039/c4ay01635a · Cited by 1
SIMULTANEOUS INHIBITION OF DRIVER AND EFFECTOR KINASES PROMOTES POTENT GROWTH ARREST OF AML CELLS IN VITRO AND IN VIVO
Weir, M. C. (2016) · D-Scholarship@Pitt (University of Pittsburgh) · Cited by 1
Cardio-oncology: Network-Based Prediction of Cancer Therapy-Induced Cardiotoxicity
Cheng, F. (2019) · Challenges and advances in computational chemistry and physics · doi:10.1007/978-3-030-16443-0_5 · Cited by 1
Cheminformatics in the Identification of Drug Classes for the Treatment of Type 2 Diabetes
Finn, P. W. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9882-1_4 · Cited by 1
Comprehensive bioinformatics analysis reveals kinase activity profiling associated with heart failure
Zhang, Z., Tian, S., Wu, C., Li, Y., Wan, J., Zhang, J., Liu, X., & Zhang, W. (2021) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29935 · Cited by 1
Basics of Polypharmacology
Wang, Z., & Yang, B. (2022) · Springer eBooks · doi:10.1007/978-3-031-04998-9_1 · Cited by 1
De NovoDesign of Ligands against Multitarget Profiles
Besnard, J., & Hopkins, A. L. (2013) · Wiley eBooks · doi:10.1002/9783527677016.ch12 · Cited by 2

Authors: Knight, Z. A., Lin, H., & Shokat, K. M.
Affiliations: Rockefeller University (US)
Howard Hughes Medical Institute (US)
Corresponding author: Knight, Zachary A.
Shokat, Kevan M.
ORCID: Knight, Zachary A.
Shokat, Kevan M.
Venue: Nature reviews. Cancer
Publisher: Springer Science and Business Media LLC
Published: 2010-02
Volume: 10
Issue: 2
Pages: 130-137
ISSN: 1474-175X (ISSN-L)
1474-1768
DOI: 10.1038/nrc2787
PMC: PMC2880454
OpenAlex: W2022609682
Cited by: 674
References: 104
Citations by year: 2026: 17 · 2025: 20 · 2024: 21 · 2023: 22 · 2022: 24 · 2021: 29 · 2020: 47 · 2019: 34 · 2018: 45 · 2017: 51 · 2016: 43 · 2015: 48 · 2014: 72 · 2013: 70 · 2012: 43
FWCI: 8.19
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature reviews. Cancer (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: Howard Hughes Medical Institute
National Institutes of Health (5r01eb001987-15)
National Institute of Diabetes and Digestive and Kidney Diseases (R00DK083531, K99DK083531)
National Institute of Biomedical Imaging and Bioengineering (R01-EB001987)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
Keywords: kinase inhibitors, polypharmacology, combination therapy, drug resistance, anticancer drug development
MeSH terms: Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Humans, Mutation, Neoplasms, Protein Kinases, Technology, Pharmaceutical, Drug Delivery Systems, Drug Resistance, Neoplasm, RNA, Small Interfering, Protein Kinase Inhibitors, Drug Discovery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Targeting the cancer kinome through polypharmacology

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks